A Study of Avastin (Bevacizumab) in Combination With Docetaxel and Cisplatin in Patients With Metastatic or Locally Advanced Non-small Cell Lung Cancer

• Status: Completed
• Trial end date: 2011-07-01
• Target enrollment: 0
• Participant gender: All

Summary

This study assessed the efficacy and safety of Avastin in combination with docetaxel and cisplatin as first-line treatment of patients with metastatic or locally advanced non-small cell lung cancer. Patients received Avastin 15 mg/kg intravenously (IV), docetaxel 75 mg/m^2, and cisplatin 75 mg/m^2 on Day 1 of each 3-week cycle for a maximum of 6 cycles.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hoffmann-La Roche
• Treatments: Bevacizumab; Cisplatin; Docetaxel

Criteria

Inclusion Criteria:

• Adult patients, ≥ 18 years of age.

• Stage IIIb or IV non-small cell lung cancer.

• Chemotherapy-naive.

Exclusion Criteria:

• Previous treatment for non-small cell lung cancer.

• Previous malignant tumor within last 5 years, except for basal cell skin cancer or preinvasive cervical cancer.

• Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to start of study.

• Recent or current chronic treatment with aspirin (> 325 mg/day).